/
/
POMALYST Receives Label Update Approval: Overall Survival & Progression Free Survival For Relapsed/Refractory Myeloma Patients
POMALYST Receives Label Update Approval: Overall Survival & Progression Free Survival For Relapsed/Refractory Myeloma Patients image
POMALYST Receives Label Update Approval: Overall Survival & Progression Free Survival For Relapsed/Refractory Myeloma Patients
Posted Apr 28, 2015

Celgene Corporation announced it has fulfilled the accelerated approval requirements for POMALYST (pomalidomide) based on results from MM-003, an international phase III study of POMALYST plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma patients. POMALYST, in combination with dexamethasone is approved for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy.

"There remains a significant unmet need for relapsed/refractory multiple myeloma patients. POMALYST has been able to help thousands of patients since its approval in 2013 and this data now confirms its survival benefits," said Jacqualyn A. Fouse, Ph.D., President, Global Hematology and Oncology for Celgene. "This label update provides important information about a key product in our industry-leading portfolio of therapies for patients with multiple myeloma." In the MM-003 study, median progression-free survival (PFS), the primary endpoint of the study, was significantly longer with POMALYST plus low-dose dexamethasone (3.6 months) than high-dose dexamethasone (1.8 months). Patients in the POMALYST plus low-dexamethasone arm had a 55% reduction in the risk of progression or death. The pre-specified, final analysis for overall survival (OS) showed a median overall survival for the POMALYST plus low-dose dexamethasone arm of 12.4 months, compared to the high-dose dexamethasone arm of 8 months. This survival benefit was statistically significant even though 53% of patients in the high-dose dexamethasone arm had subsequently received POMALYST. POMALYST was initially approved by the FDA in February 2013 under the agency's accelerated approval program based on the phase II study, MM-002. For more information, click here.
The author Lizzy Smith

about the author
Lizzy Smith

Lizzy Smith was diagnosed with myeloma in 2012 at age 44. Within days, she left her job, ended her marriage, moved, and entered treatment. "To the extent I'm able, I want to prove that despite life's biggest challenges, it is possible to survive and come out stronger than ever," she says.

More Myeloma News Articles

Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Genentech
Abbvie
Bristol Myers Squibb
Janssen Oncology
GSK

Follow Us

facebook instagram twitter youtube

Copyright © 2022 HealthTree Foundation. All Rights Reserved.

The HealthTree Foundation / Myeloma Crowd is a qualified 501(c)(3) tax-exempt organization. Tax ID 45-5354811

 https://www.guidestar.org/profile/45-5354811